HomeJapan TimesJapan Times·Jun 23, 2026·1 min readPfizer’s lung cancer drug trial fails to boost survivalPatients given the drug, called sigvotatug vedotin, didn't live significantly longer than those given standard therapy.View original source — Japan Times ↗ShareCopy linkShare on XShare on FacebookRelated storiesESPNSportsJun 23, 2026 · 1 minManfred: Giants' Pride cap guidance was 'not clear...ESPNESPNSportsJun 23, 2026 · 1 minHaaland nets 2 more as Norway clinch knockoutsESPNESPNSportsJun 23, 2026 · 1 minNight of Champions: How to watch, schedule on ESPN...ESPNESPNSportsJun 23, 2026 · 1 minSources: Randle off to Nets as part of 3-team deal...ESPN